



Market Announcement

15 December 2021

Palla Pharma Limited (ASX: PAL) – Suspension from Quotation

Description

The securities of Palla Pharma Limited ('PAL') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAL, pending the release of an announcement regarding the results of the review undertaken by PAL of its strategy and operations.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



PALLA PHARMA

14 December 2021

By E-mail: Melissa.Kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au

Listings Compliance Adviser
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

Dear Ms Kostopoulos

Palla Pharma Limited- request for suspension

We refer to the request of 13 December 2021 for a trading halt in respect of the shares of Palla Pharma Limited (ACN 107 872 453) (ASX:PAL) (**PAL**).

PAL now requests, pursuant to Listing Rule 17.2, that its securities be suspended from quotation from the commencement of trading on 15 December 2021 (immediately after the cessation of the trading halt).

The suspension is requested to provide PAL with additional time to complete the review undertaken by PAL of its strategy and operations (as referred to in the trading halt request) and to consider matters arising from the review.

PAL expects that:

- the suspension will continue for a period of up to 5 trading days; and
- the suspension will end upon the release of an announcement by PAL in connection with the review.

PAL is not aware of any reason why its shares should not be suspended, nor is it aware of any other information required to be provided to the market or ASX in relation to the suspension.

Should you require any other information, please do not hesitate to contact me.

Yours sincerely

Mark Licciardo
Company Secretary
Palla Pharma Limited